Jonathan Allan, GENERAL COUNSEL & Corporate Secretary at Stoke Therapeutics, Inc. (STOK), sold 627 shares at $26.33 ($17K) on 2026-10-02, disclosed to the SEC on 2026-10-02.
Scheduled sale ($17k) by GENERAL COUNSEL & Corporate Secretary under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Negative factors outweigh the positive ones.
| Filing → |
| STOK | SELL | 2026-03-24 | $626K | — | Filing → |
| STOK | SELL | 2026-03-19 | $569K | — | Filing → |
| STOK | SELL | 2025-12-10 | $216K | — | Filing → |